Proteasome inhibition attenuates coxsackievirus-induced myocardial damage in mice

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 295, Issue 1, 2008, Pages

  Gao, Guang ^a   Zhang, Jingchun ^a   Si, Xiaoning ^a   Wong, Jerry ^a   Cheung, Caroline ^a   McManus, Bruce ^a   Luo, Honglin ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Myocardial injury; Myocarditis; Proteasome inhibitor; Ubiquitin proteasome system

Indexed keywords

PROTEASOME; UBIQUITIN; ANTIVIRUS AGENT; CAPSID PROTEIN; PROTEINASE INHIBITOR; UBIQUITIN CONJUGATING ENZYME; UBIQUITIN PROTEIN LIGASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; COXSACKIE VIRUS; HEART MUSCLE CELL; HEART MUSCLE INJURY; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; MYOCARDITIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRUS REPLICATION; A J MOUSE; ANIMAL; CELL LINE; COXSACKIE VIRUS INFECTION; DISEASE MODEL; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; ENTEROVIRUS; ENZYMOLOGY; GROWTH, DEVELOPMENT AND AGING; METABOLISM; PATHOGENICITY; PATHOLOGY; SUBCUTANEOUS DRUG ADMINISTRATION; TIME; VIROLOGY; VIRUS CULTURE; WESTERN BLOTTING;

ANIMALS; ANTIVIRAL AGENTS; BLOTTING, WESTERN; CAPSID PROTEINS; CELL LINE; COXSACKIEVIRUS INFECTIONS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENTEROVIRUS B, HUMAN; IMMUNOHISTOCHEMISTRY; INJECTIONS, SUBCUTANEOUS; MALE; MICE; MICE, INBRED A; MYOCARDITIS; MYOCYTES, CARDIAC; PLAQUE ASSAY; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; TIME FACTORS; UBIQUITIN; UBIQUITIN-ACTIVATING ENZYMES; UBIQUITIN-CONJUGATING ENZYMES;

EID: 49849105825     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00292.2008     Document Type: Article

References (43)

1. Adams J. Development of the proteasome inhibitor PS-341. Oncologist 7: 9-16, 2002.
2. Adams J, Behnke M, Chen S, Cruickshank AA, Dick LR, Grenier L, Klunder JM, Ma YT, Plamondon L, Stein RL. Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorg Med Chem Lett 8: 333-338, 1998.
3. Ciechanover A. The ubiquitin-proteasome pathway: on protein death and cell life. EMBO J 17: 7151-7160, 1998.
4. Dec GW Jr, Palacios IF, Fallon JT, Aretz HT, Mills J, Lee DC, Johnson RA. Active myocarditis in the spectrum of acute dilated cardiomyopathies. Clinical features, histologic correlates, and clinical outcome. N Engl J Med 312: 885-890, 1985.
5. Fairweather D, Rose NR. Inflammatory heart disease: a role for cytokines. Lupus 14: 646-651, 2005.
6. Feldman AM, McNamara D. Myocarditis. N Engl J Med 343: 1388-1398, 2000.
7. Gao G, Luo H. The ubiquitin-proteasome pathway in viral infections. Can J Physiol Pharmacol 84: 5-14, 2006.
8. Glickman MH, Ciechanover A. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev 82: 373-428, 2002.
9. Golab J, Bauer TM, Daniel V, Naujokat C. Role of the ubiquitinproteasome pathway in the diagnosis of human diseases. Clin Chim Acta 340: 27-40, 2004.
10. Grist NR, Reid D. Organisms in myocarditis/endocarditis viruses. J Infect 34: 155, 1997.
11. Herrmann J, Ciechanover A, Lerman LO, Lerman A. The ubiquitinproteasome system in cardiovascular diseases - a hypothesis extended. Cardiovasc Res 61: 11-21, 2004.
12. Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem 67: 425-479, 1998.
13. Huber SA, Lodge PA. Coxsackievirus B-3 myocarditis in Balb/c mice. Evidence for autoimmunity to myocyte antigens. Am J Pathol 116: 21-29, 1984.
14. Knowlton KU, Badorff C. The immune system in viral myocarditis: maintaining the balance. Circ Res 85: 559-561, 1999.
15. Li YP, Chen Y, John J, Moylan J, Jin B, Mann DL, Reid MB. TNF-alpha acts via p38 MAPK to stimulate expression of the ubiquitin ligase atrogin1/MAFbx in skeletal muscle. FASEB J 19: 362-370, 2005.
16. Li YP, Lecker SH, Chen Y, Waddell ID, Goldberg AL, Reid MB. TNF-alpha increases ubiquitin-conjugating activity in skeletal muscle by up-regulating UbcH2/E220k. FASEB J 17: 1048-1057, 2003.
17. Llovera M, Carbo N, Lopez-Soriano J, Garcia-Martinez C, Busquets S, Alvarez B, Agell N, Costelli P, Lopez-Soriano FJ, Celada A, Argiles JM. Different cytokines modulate ubiquitin gene expression in rat skeletal muscle. Cancer Lett 133: 83-87, 1998.
18. Luo H, Zhang J, Cheung C, Suarez A, McManus BM, Yang D. Proteasome inhibition reduces coxsackievirus B3 replication in murine cardiomyocytes. Am J Pathol 163: 381-385, 2003.
19. Luo H, Zhang J, Dastvan F, Yanagawa B, Reidy MA, Zhang HM, Yang D, Wilson JE, McManus BM. Ubiquitin-dependent proteolysis of cyclin D1 is associated with coxsackievirus-induced cell growth arrest. J Virol 77: 1-9, 2003.
20. Martino TA, Liu P, Sole MJ. Viral infection and the pathogenesis of dilated cardiomyopathy. Circ Res 74: 182-188, 1994.
21. Masucci MG. Epstein-Barr virus oncogenesis and the ubiquitin-proteasome system. Oncogene 23: 2107-2115, 2004.
22. McManus BM, Chow LH, Radio SJ, Tracy SM, Beck MA, Chapman NM, Klingel K, Kandolf R. Progress and challenges in the pathological diagnosis of myocarditis. Eur Heart J 12, Suppl D: 18-21, 1991.
23. McManus BM, Chow LH, Wilson JE, Anderson DR, Gulizia JM, Gauntt CJ, Klingel KE, Beisel KW, Kandolf R. Direct myocardial injury by enterovirus: a central role in the evolution of murine myocarditis. Clin Immunol Immunopathol 68: 159-169, 1993.
24. McManus BM, Yanagawa B, Rezai N, Luo H, Taylor L, Zhang M, Yuan J, Buckley J, Triche T, Schreiner G, Yang D. Genetic determinants of coxsackievirus B3 pathogenesis. Ann NY Acad Sci 975: 169-179, 2002.
25. Myung J, Kim KB, Crews CM. The ubiquitin-proteasome pathway and proteasome inhibitors. Med Res Rev 21: 245-273, 2001.
26. Naujokat C, Hoffmann S. Role and function of the 26S proteasome in proliferation and apoptosis. Lab Invest 82: 965-980, 2002.
27. Pickart CM. Mechanisms underlying ubiquitination. Annu Rev Biochem 70: 503-533, 2001.
28. Schwartz AL, Ciechanover A. The ubiquitin-proteasome pathway and pathogenesis of human diseases. Annu Rev Med 50: 57-74, 1999.
29. Schwimmbeck PL, Badorff C, Schultheiss HP, Strauer BE. Transfer of human myocarditis into severe combined immunodeficiency mice. Circ Res 75: 156-164, 1994.
30. Shackelford J, Pagano JS. Tumor viruses and cell signaling pathways: deubiquitination versus ubiquitination. Mol Cell Biol 24: 5089-5093, 2004.
31. Si X, McManus BM, Zhang J, Yuan J, Cheung C, Esfandiarei M, Suarez A, Morgan A, Luo H. Pyrrolidine dithiocarbamate reduces coxsackievirus B3 replication through inhibition of the ubiquitin-proteasome pathway. J Virol 79: 8014-8023, 2005.
32. Simms MG, Walley KR. Activated macrophages decrease rat cardiac myocyte contractility: importance of ICAM-1-dependent adhesion. Am J Physiol Heart Circ Physiol 277: H253-H260, 1999.
33. Tam PE. Coxsackievirus myocarditis: interplay between virus and host in the pathogenesis of heart disease. Viral Immunol 19: 133-146, 2006.
34. Tanaka K, Kawakami T, Tateishi K, Yashiroda H, Chiba T. Control of IkappaBalpha proteolysis by the ubiquitin-proteasome pathway. Biochimie 83: 351-356, 2001.
35. Vu PK, Sakamoto KM. Ubiquitin-mediated proteolysis and human disease. Mol Genet Metab 71: 261-266, 2000.
36. Weekes J, Morrison K, Mullen A, Wait R, Barton P, Dunn MJ. Hyperubiquitination of proteins in dilated cardiomyopathy. Proteomics 3: 208-216, 2003.
37. Weissman AM. Themes and variations on ubiquitylation. Nat Rev Mol Cell Biol 2: 169-178, 2001.
38. Wilkinson KD. Ubiquitination and deubiquitination: targeting of proteins for degradation by the proteasome. Semin Cell Dev Biol 11: 141-148, 2000.
39. Wing SS. Deubiquitinating enzymes - the importance of driving in reverse along the ubiquitin-proteasome pathway. Int J Biochem Cell Biol 35: 590-605, 2003.
40. Woodruff JF, Woodruff JJ. Involvement of T lymphocytes in the pathogenesis of coxsackie virus B3 heart disease. J Immunol 113: 1726-1734, 1974.
41. Yanagawa B, Spiller OB, Choy J, Luo H, Cheung P, Zhang HM, Goodfellow IG, Evans DJ, Suarez A, Yang D, McManus BM. Coxsackievirus B3-associated myocardial pathology and viral load reduced by recombinant soluble human decay-accelerating factor in mice. Lab Invest 83: 75-85, 2003.
42. Yanagawa B, Spiller OB, Proctor DG, Choy J, Luo H, Zhang HM, Suarez A, Yang D, McManus BM. Soluble recombinant coxsackievirus and adenovirus receptor abrogates coxsackievirus B3-mediated pancreatitis and myocarditis in mice. J Infect Dis 189: 1431-1439, 2004.
43. Yuan J, Zhang J, Wong BW, Si X, Wong J, Yang D, Luo H. Inhibition of glycogen synthase kinase 3beta suppresses coxsackievirus-induced cytopathic effect and apoptosis via stabilization of beta-catenin. Cell Death Differ 12: 1097-1106, 2005.